Free PSA Test Awarded US Patent

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 5
Volume 5
Issue 5

ABBOTT PARK, Ill--Abbott Laboratories and the Finnish-based company Wallac Oy, a subsidiary of EG&G Inc. (Wellesley, Mass), have received a US patent for two methods of assaying free PSA (prostate-specific antigen).

ABBOTT PARK, Ill--Abbott Laboratories and the Finnish-based companyWallac Oy, a subsidiary of EG&G Inc. (Wellesley, Mass), havereceived a US patent for two methods of assaying free PSA (prostate-specificantigen).

The patent was issued to two inventors, Dr. Ulf-Hakan Stenman,of Helsinki University Central Hospital, and Dr. Hans Lilja, ofLund University.

The inventors gave exclusive rights to Wallac, which subsequentlygranted a sublicense to Abbott. The patent covers immmunoassaysfor free PSA and the use of the ratio of free-to-total PSA tobetter distinguish between prostate cancer and benign prostatichyperplasia (BPH).

Articles in this issue
No Need to Delay Mammography After FNA, Study Shows
Pediatric Cancer Guidelines Are a National Effort
EPA Proposes Changes in Determining Cancer Risk of Chemicals, Pollutants
ATL's HDI Digital Ultrasound Is Approved for Breast Indication
Cell-Adhesion Molecules May Be Key to Controlling Metastases in Breast Cancer
NIH Study Suggests That 200 mg Is The Optimal Daily Dose of Vitamin C
Natural History of HIV Supports the Use Of Early Interventions
Aids Vaccine Trial Fails to Show Clinical Benefit
Rep. Porter Honored For Work on Budget
Forum Airs Issue of Who Should Pay for Patient Care in Cancer Clinical Trials
Blenoxane Cleared for New Use In Malignant Pleural Effusion
Implementation of Critical Path Reduces Prostatectomy Costs
Berlex Foundation Seeks Workshop Applicants
Networking Venture Benefits Both
Health of Biotech Industry a Concern to Oncologists

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
4 experts in this video
4 experts in this video
4 experts in this video
4 experts in this video
1 expert in this video
1 expert in this video
1 expert in this video
Related Content
Landmark Radioligand Therapy Approval Bridges Treatment Gap in mCRPC

Landmark Radioligand Therapy Approval Bridges Treatment Gap in mCRPC

Ariana Pelosci
April 18th 2025
Article

Administering 177Lu for mCRPC is a “team sport”, according to Steven Finkelstein, MD, DABR, FACRO.

Navigating Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer

Navigating Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;David Morris, MD, MS;Tanya B. Dorff, MD;Mark T. Fleming, MD
March 5th 2025
Podcast

A patient case of a 50-year-old man with hormone-sensitive prostate cancer sparked a debate among oncologists regarding the best course of action.

Pembrolizumab/Docetaxel Does Not Improve OS/rPFS Outcomes in mCRPC

Pembrolizumab/Docetaxel Does Not Improve OS/rPFS Outcomes in mCRPC

Tim Cortese
April 15th 2025
Article

Results from the KEYNOTE-921 trial demonstrated that pembrolizumab with docetaxel did not elicit efficacy improvements vs placebo with docetaxel in prostate cancer.

AI tools may show utility in areas such as prostate diagnostic imaging, pathology, and treatment outcome predictions.

Leveraging Artificial Intelligence Evolutions in Prostate Cancer Care

James B. Yu, MD, MHS, FASTRO;Julian C. Hong, MD, MS
July 1st 2024
Podcast

AI tools may show utility in areas such as prostate diagnostic imaging, pathology, and treatment outcome predictions.

Results from PSMAfore show that lutetium Lu 177 vipivotide tetraxetan elicited a median rPFS of 9.3 months vs 5.6 months with ARPI in prostate cancer.

FDA Approves Radioligand Therapy in PSMA–Positive, Castration-Resistant PC

Tim Cortese
March 28th 2025
Article

Results from PSMAfore show that lutetium Lu 177 vipivotide tetraxetan elicited a median rPFS of 9.3 months vs 5.6 months with ARPI in prostate cancer.

Post-Radical Prostatectomy PSA Levels Reduced Overtreatment Risk After 3 Months

Post-Radical Prostatectomy PSA Levels Reduced Overtreatment Risk After 3 Months

Tim Cortese
March 26th 2025
Article

A cohort study found that pre-radical prostatectomy levels greater than 20 ng/mL were associated with increased all-cause mortality risk and prostate cancer-specific mortality risk.